drugset / Trial / NCT00024167
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
Phase 3
Terminated
265 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases. PURPOSE: This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone.
Timeline
- Start
- 2002-04
- Primary completion
- 2014-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Ketoconazole | Small molecule | 400 mg | Oral |
| Subject | Prednisone | Other / unclassified | 5 mg | Oral |
| Subject | Vinblastine | Small molecule | 4 mg/m2 | Intravenous |
| Subject | estramustine | Other / unclassified | 140 mg | Oral |
| Subject | strontium-89 | Other / unclassified | 148 mbq | Intravenous |
| Background | Dexamethasone | Small molecule | 4 mg | Oral |